285 related articles for article (PubMed ID: 28912139)
21. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
22. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
23. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
24. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine.
Pisano C; Vesci L; Milazzo FM; Guglielmi MB; Foderà R; Barbarino M; D'Incalci M; Zucchetti M; Petrangolini G; Tortoreto M; Perego P; Zuco V; Orlandi A; Passeri D; Carminati P; Cavazza C; Zunino F
Clin Cancer Res; 2010 Aug; 16(15):3944-53. PubMed ID: 20562210
[TBL] [Abstract][Full Text] [Related]
25. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
Voortman J; Goto A; Mendiboure J; Sohn JJ; Schetter AJ; Saito M; Dunant A; Pham TC; Petrini I; Lee A; Khan MA; Hainaut P; Pignon JP; Brambilla E; Popper HH; Filipits M; Harris CC; Giaccone G
Cancer Res; 2010 Nov; 70(21):8288-98. PubMed ID: 20978195
[TBL] [Abstract][Full Text] [Related]
27. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
28. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
[No Abstract] [Full Text] [Related]
29. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
30. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
31. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
[TBL] [Abstract][Full Text] [Related]
32. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
Schuette W; Behringer D; Stoehlmacher J; Kollmeier J; Schmager S; Fischer von Weikersthal L; Schumann C; Buchmann J
Clin Lung Cancer; 2015 Nov; 16(6):447-56. PubMed ID: 26094080
[TBL] [Abstract][Full Text] [Related]
33. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
34. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
35. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.
Nascimento AV; Gattacceca F; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Nanomedicine (Lond); 2016 Apr; 11(7):767-81. PubMed ID: 26980454
[TBL] [Abstract][Full Text] [Related]
37. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
38. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
40. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
